Donatti Amanda, Canto Amanda M, Godoi Alexandre B, da Rosa Douglas C, Lopes-Cendes Iscia
Department of Medical Genetics and Genomic Medicine, School of Medical Sciences, University of Campinas (UNICAMP), Tessália Vieira de Camargo, 126 Cidade Universitária "Zeferino Vaz", Campinas SP 13083-887, Brazil.
Brazilian Institute of Neuroscience and Neurotechnology, Campinas SP 13083-887, Brazil.
Metabolites. 2020 Sep 29;10(10):389. doi: 10.3390/metabo10100389.
There are, still, limitations to predicting the occurrence and prognosis of neurological disorders. Biomarkers are molecules that can change in different conditions, a feature that makes them potential tools to improve the diagnosis of disease, establish a prognosis, and monitor treatments. Metabolites can be used as biomarkers, and are small molecules derived from the metabolic process found in different biological media, such as tissue samples, cells, or biofluids. They can be identified using various strategies, targeted or untargeted experiments, and by different techniques, such as high-performance liquid chromatography, mass spectrometry, or nuclear magnetic resonance. In this review, we aim to discuss the current knowledge about metabolites as biomarkers for neurological disorders. We will present recent developments that show the need and the feasibility of identifying such biomarkers in different neurological disorders, as well as discuss relevant research findings in the field of metabolomics that are helping to unravel the mechanisms underlying neurological disorders. Although several relevant results have been reported in metabolomic studies in patients with neurological diseases, there is still a long way to go for the clinical use of metabolites as potential biomarkers in these disorders, and more research in the field is needed.
预测神经疾病的发生和预后仍然存在局限性。生物标志物是在不同条件下会发生变化的分子,这一特性使其成为改善疾病诊断、确定预后和监测治疗的潜在工具。代谢物可作为生物标志物,是在不同生物介质(如组织样本、细胞或生物流体)中发现的源自代谢过程的小分子。可以使用各种策略、靶向或非靶向实验以及不同技术(如高效液相色谱法、质谱法或核磁共振)来鉴定它们。在本综述中,我们旨在讨论有关代谢物作为神经疾病生物标志物的当前知识。我们将介绍最近的进展,这些进展表明在不同神经疾病中识别此类生物标志物的必要性和可行性,并讨论代谢组学领域的相关研究结果,这些结果有助于揭示神经疾病的潜在机制。尽管在神经疾病患者的代谢组学研究中已经报道了一些相关结果,但代谢物作为这些疾病潜在生物标志物的临床应用仍有很长的路要走,该领域还需要更多的研究。